# Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants

> **NCT03965728** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 67 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BAY1830839
- **DRUG:** Placebo
- **DRUG:** Midazolam
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT03965728
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-05
- **Primary completion:** 2022-01-21
- **Final completion:** 2022-05-11
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965728, "Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03965728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*